Global Dengue Vaccines Market Growth (Status and Outlook) 2024-2030

Global Dengue Vaccines Market Growth (Status and Outlook) 2024-2030

Dengue vaccine is a vaccine used to prevent dengue fever in humans. As of 2019, one version is commercially available, known as CYD-TDV, and sold under the brand name Dengvaxia. The vaccine is only recommended in those who have previously had dengue fever or populations in which most people have been previously infected. The value of the vaccine is limited by the fact that it may worsen outcomes in those who have not previously been infected. It is given as three injections over a year.

The global Dengue Vaccines market size is projected to grow from US$ 512 million in 2024 to US$ 1174 million in 2030; it is expected to grow at a CAGR of 14.8% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Dengue Vaccines Industry Forecast” looks at past sales and reviews total world Dengue Vaccines sales in 2022, providing a comprehensive analysis by region and market sector of projected Dengue Vaccines sales for 2023 through 2029. With Dengue Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dengue Vaccines industry.

This Insight Report provides a comprehensive analysis of the global Dengue Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Dengue Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Dengue Vaccines market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dengue Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dengue Vaccines.

The only one version which is commercially available now, known as Dengvaxia and produced by Sanofi, don't has enough efficacy. While there are several vaccines are on trial now. TAK-003, developed by Takeda is one stride closer to reaching the sizable market waiting for dengue vaccines as it reports positive top-line results from a massive Phase III trial.

This report presents a comprehensive overview, market shares, and growth opportunities of Dengue Vaccines market by product type, application, key players and key regions and countries.

Segmentation by Type:
Dengvaxia
TAK-003
Others

Segmentation by Application:
Public Sector
Private Sector

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Dengvaxia
TAK-003
Others

Segmentation by Application:
Public Sector
Private Sector

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sanofi
Takeda

Please note: The report will take approximately 2 business days to prepare and deliver.